GlaxoSmithKline (GSK) is a focused biopharma company with strong momentum and ambitious goals, bringing together science, technology, and talent to get ahead of disease. With a heritage dating back to the 18th century, GSK is a UK-based company distinguished by its strong portfolio of both conventional and innovative medicines and vaccines. It operates in 75 countries and employs more than 65,000 people.
Recognized five times with the Nobel Prize in Medicine for its scientific research and innovative products, GSK invested GBP 6.4 billion in R&D in 2024 and, as a pioneer in healthcare innovation, has approximately 71 drugs and vaccines in development.
GSK focuses on the science of the immune system and advanced technologies, investing across four core therapeutic areas, including respiratory, immunology and inflammation, oncology, and HIV and infectious diseases, to deliver impact at scale.
As part of its ambition to positively impact the health of 2.5 billion people by the end of 2030 by making its medicines and vaccines as widely accessible as possible, GSK has long supplied oral polio vaccine to UNICEF.
GSK has partnered with Gavi, the Vaccine Alliance, since 2000 and has supplied more than one billion vaccine doses since 2010, helping to protect millions of children worldwide. Gavi funds immunization programs in countries with a gross national income (GNI) per capita below USD 1,630. Countries eligible for Gavi support always receive the lowest prices, which can be as little as one-tenth of those charged in high-income countries. In 2024, GSK delivered approximately 6 million doses of cervical cancer vaccine, around 45 million doses of pneumococcal vaccine, and 43 million doses of rotavirus vaccine.
In Türkiye, GSK has been contributing to public health for more than 65 years. Prior to the launch of the Pharmaceutical Product Localization Project in 2016, the company initiated local production of 31 products in collaboration with two local manufacturing partners, enabling the localization of Türkiye’s largest-volume antibiotic portfolio. Following an investment of over GBP 30 million, GSK increased the number of its local manufacturing partners from two to four and plans to further expand its local manufacturing activities in Türkiye.
GSK continues to advance its investments in an environment that actively encourages localization within the Turkish pharmaceutical industry. In 2018, the company launched a manufacturing collaboration with a local partner, supported by an investment of GBP 25 million, to transfer the production of nebulizer technology used in respiratory treatment and a patented HIV product to Türkiye.
Through both its healthcare solutions and social responsibility initiatives, GSK has contributed to Türkiye’s future. In collaboration with the Community Volunteers Foundation, GSK reached 4.2 million people between 2018 and 2022 through the “Say Stop at Red!” project, which aimed to raise awareness of rights, especially the rights of children and women to speak up. GSK also provided TRY 1 million in support to those affected by the February 2023 earthquakes and, in October 2023, established a Support Centre in Adıyaman to deliver psychosocial assistance across all earthquake-affected areas, with a special focus on children. In 2025, the Support Centre engaged more than 53,000 participants through over 2,000 organized events.